Proactive’s Post

Please read about the promising results from the first cohort of three patients in our Deltacel-01 Phase 1 clinical trial at Beverly Hills Cancer Center. "Consistency in safety, tolerability, and disease stability is of paramount importance at this stage of testing, and the data thus far bolster our confidence in Deltacel's potential as a transformative treatment," stated Pietro Bersani, Chief Executive Officer of Kiromic BioPharma. “The findings are especially promising considering the robustness of response in the absence of brain metastasis, and the notable reduction in tumor size for the second and the first patient, respectively." #cartcelltherapy #celltherapy #patientsfirst https://lnkd.in/eVycTBzU

Imugene Limited (ASX:IMU, OTC:IUGNF) CEO Leslie Chong joins Jonathan Jackson in the Proactive studio this morning to discuss encouraging results from the company’s Phase 1 Metastatic Advanced Solid Tumours trial, evaluating the safety and efficacy of its novel #CancerKillingVirus #CF33-hNIS (VAXINIA). In exceptional news for the company, one patient with #BiliaryTractCancer achieved a Complete Response after being treated at a mid-dose level and has remained in #remission for over 430 days. Two Partial Responses were also observed in #melanoma patients at a mid-dose level. Imugene will now move to a dose escalation phase. Early results were presented at the American Society of Clinical Oncology - Gastrointestinal Cancer Symposium (ASCO-GI) in San Francisco, California. Chong discusses what that means for the company and what shareholders can expect in 2024. Watch at #Proactive #ProactiveInvestors #CancerTreatment http://ow.ly/B2eG1059FQP

Exciting News for our community! A Phase 2 study has just started evaluating ulixertinib, a first-in-class ERK 1/2 inhibitor being developed by Biomed Valley Discoveries, for treating histiocytosis. This rare disorder causes abnormal white blood cell growth, leading to serious health issues. Dr. Eli Diamond from Memorial Sloan Kettering Cancer Center leads this study, building on promising results from patients who previously tried ulixertinib. This new approach could offer a breakthrough for those who don't respond to current treatments. We are hopeful that ulixertinib will bring a much-needed new treatment option for histiocytosis patients! Learn more about this exciting development by clicking this link: https://lnkd.in/enPPCnBT #Histiocytosis #Ulixertinib #BiomedValleyDiscoveries #NewHope #CancerResearch #ClinicalTrials #PatientCare #MedicalBreakthrough

👏 We are excited to announce that AmoyDx® Pan Lung Cancer PCR Panel has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) as a companion diagnostic for TABRECTA™ (capmatinib) – designed for patients with unresectable, advanced, or recurrent non-small cell lung cancer (NSCLC) with MET exon 14 (METex14) skipping alterations. 🎆 The AmoyDx PLC Panel detects alterations across 11 critical driver genes and identifies actionable mutations in seven of these genes which are directly linked to twelve targeted NSCLC therapies. This approval marks a significant advancement in precision cancer treatment with the potential to significantly enhance patient outcomes. Read the full press release here 👉 : https://lnkd.in/g9BRamEn #PrecisionMedicine #Oncology #NSCLC #LungCancer #Cancer

Cancer is a fibrotic disease—and last year the FDA issued a Letter of Support for the inclusion of our nordicPRO-C3™ biomarker in tumor fibrosis studies. Active tumor fibrosis is the leading factor in cold, dense, hypoxic, and collagen-rich tumors. Watch Nicholas Willumsen, Director of Oncology at Nordic Bioscience, discuss how the FDA's endorsement may impact clinical decision-making and patient outcomes. PRO-C3 is measured on the Roche Diagnostics cobas® e automated platform, increasing robustness and accuracy in sample measurements and enabling future in-vitro diagnostic (IVD) use. Morten Asser Karsdal Neel Ingemann N. Claus S. von Arenstorff Daniel Gabor #FDA #DrugDevelopment #TumorFibrosis #CancerReserach #ClinicalTrials

Imugene Limited (ASX:IMU, OTC:IUGNF) managing director and CEO Leslie Chong and strategic advisor Dr Yuman Fong sit down with Proactive’s Jonathan Jackson to discuss Professor Fong’s expertise and the latest company developments. Dr Fong is a world-renowned #cancer researcher, physician and surgeon whose clinical work has focused on OV for more than 30 years. He is the inventor of OV CF33. Imugene has dosed the first patient in its trial for #BileTractCancer (cholangiocarcinoma) patients. The MAST (metastatic advanced solid tumours) Phase 1 trial has been expanded due to early responses in gastrointestinal cancers, particularly cholangiocarcinoma, using Imugene’s cancer-killing virus CF33, known as #VAXINIA. The trial, held at St Vincent’s Hospital, Melbourne, Australia, expects to enrol 10 patients. Watch at #Proactive #ProactiveInvestors #Biotech #Biopharmaceutcials #Oncology #OncolyticVirus https://lnkd.in/eGaibfwJ

Pre-targeting: The Next Generation of Cancer Treatment! By sequentially administering the targeting molecule and radioligand, pre-targeting leverages the tumor-targeting properties of antibodies while avoiding their pharmacokinetic limitations. This strategy reduces radioactivity in healthy tissues, shortens circulation time, and optimizes the high dose-rate potential of short-lived radionuclides such as Pb-212. Learn more about our company’s pre-targeting platform -> https://lnkd.in/eBr3zAT6

Serum biomarker signature is predictive of the risk of hepatocellular cancer in patients with cirrhosis. https://ow.ly/nEeI50SyTve

During the 2024 #AACR Annual Meeting this week, the concept of #metastasis has dramatically changed since its last plenary session 14 years ago.... David Lyden's session on "Evolution of the Genome, Microenvironment, and Host through Metastasis" reveals new insights on the importance of tumor-secreted factors and extracellular vesicles (EVPs) which can have downstream effect on different organs and can contribute towards a systemic effect. As Lyden's team discovered, EVPs as a result of a pancreatic tumor can disrupt the liver's function, increase the side effects of chemotherapy and even increase the likelihood of metastases outside the liver. Said differently, “if you have cancer going to the lung, you can’t ignore that you have a fatty liver as well.” The evolving understanding of metastasis emphasizes the need for a more comprehensive approach to cancer research and treatment. To learn more about his work and conference insights, continue reading here: https://lnkd.in/g_XJB3ed #Pharmaceutical #Biotech #Diagnoses #Medicine #Clinical #Healthcare #Lifescience #CancerResearch #CancerTreatment #CancerCells #Oncology #MedicalResearch #Healthcare #CancerAwareness #CancerBiology #InnovationInMedicine #HealthcareIndustry #CancerPrevention #CancerScience #HealthScience #MedicalCommunity #CancerEducation

This content is intended for U.S. audiences only.     At the upcoming #ASCO24, we’re presenting more than 100 abstracts across multiple tumor types, including data from three pivotal Phase III trials, including two back-to-back #Lungcancer plenaries and a late-breaking special session in #Breastcancer: bit.ly/3KaeVnE    Visit the link to read more about our aim to:  - Transform treatment expectations across earlier-stage #Lungcancer settings   - Redefine outcomes across subtypes and stages of #Breastcancer   - Advance the next wave of medicines and combination therapies to attack cancer from multiple angles